运动干预在老年糖尿病周围神经病变患者中的应用效果

目的 观察运动干预对老年糖尿病周围神经病变患者下肢血管功能、周围神经传导功能的影响。 方法 选取2017年12月—2019年1月丽水市第二人民医院老年科收治的首次诊断为老年糖尿病周围神经病变患者90例,按照完全随机法随机分为对照组和观察组,各45例,2组患者均行临床常规治疗,观察组在常规治疗的基础上联合运动干预治疗。抽取2组患者治疗前后静脉血,计算BMI,观察2组患者血糖、血脂、下肢血管功能、周围神经传导功能、糖尿病周围神经病变、下肢运动功能、生活质量。 结果 观察组治疗后内膜中层厚度(IMT)、收缩期血管峰值血流速度(PSV)、血管内皮生长因子(VEGF)、可溶性血管内皮生长因子受体-2(sVEGF-2)分别为(0.21±0.06)mm、(36.74±1.70)cm/s、(85.01±5.97)pg/mL、(5.51±0.19)ng/mL,低于观察组治疗前及对照组治疗后(均P<0.05);观察组治疗后周围神经传导速度分别为(56.68±3.48)m/s、(67.66±5.42)m/s、(37.72±3.75)m/s、(54.77±3.86)m/s、(64.69±4.45)m/s,高于观察组治疗前及对照组治疗后(均P<0.05)。 结论 对老年糖尿病周围神经病变患者进行运动干预,可改善患者周围神经传导功能与下肢运动能力,减轻症状,提高患者生活质量。      

Immunogenicity of the hepatitis A vaccine 20 years after infant immunization

To determine the duration of immunity provided by the Hepatitis A vaccination (HepA), we evaluated a cohort of participants in Alaska 20 years after being immunized as infants. At recruitment, participants received two doses of inactivated HepA vaccine on one of three schedules. We conducted hepatitis A antibody (anti-HAV) testing for participants at the 20-year time-point. Seventy-five of the original 183 participants (41%) were available for follow-up. The overall anti-HAV geometric mean concentration was 29.9 mIU/mL (95% CI 22.4 mIU/mL, 39.7 mIU/mL) and 50 participants (68%) remained seropositive (titer ≥ 20 mIU/mL). Using a fractional polynomial model, the predicted percent seropositive at 25 years was 55.3%, 49.8% at 30 years and 45.7% at 35 years, suggesting that the percent sero-positive could drop below 50% earlier than previously expected. Further research is necessary to understand if protection continues after seropositivity diminishes or if a HepA booster dose may become necessary.     

Epstein-Barr virus-related encephalitis in a young woman: A case report

Although infectious mononucleosis due to Epstein-Barr virus (EBV) is a common disease among young individuals, central nervous system (CNS) complications are rare. In this report, we describe a case of CNS complications caused by EBV in a previously healthy young woman. She presented to our hospital with a 9-day history of headache and sore throat, followed by the development of fever and facial edema 6 days prior to admission. On Day 2 of admission, she was confused (Glasgow Coma Scale score: 10 points) and had fever, muscle weakness in her right arm and leg, stiff neck, and roving eye movement. We detected EBV in a cerebrospinal fluid (CSF) sample using a polymerase chain reaction (PCR) test. The magnetic resonance imaging of her brain revealed dural enhancement and right parietal and temporal lobe lesions. She was treated with acyclovir and high-dose steroid therapy. She responded well to treatment, recovered without neurologic sequelae, and was discharged home on Day 12.Our experience suggests that PCR detection of EBV DNA in CSF may be useful in diagnosing EBV encephalitis and that prognosis may be associated with an area of the brain that is affected and the time from symptom onset to starting treatment.